BRCAness profile of sporadic ovarian cancer predicts disease recurrence.

<h4>Background</h4>The consequences of defective homologous recombination (HR) are not understood in sporadic ovarian cancer, nor have the potential role of HR proteins other than BRCA1 and BRCA2 been clearly defined. However, it is clear that defects in HR and other DNA repair pathways...

Full description

Bibliographic Details
Main Authors:	Weiya Z Wysham, Paulette Mhawech-Fauceglia, Hong Li, Laura Hays, Suzanna Syriac, Tijana Skrepnik, Jay Wright, Nupur Pande, Maureen Hoatlin, Tanja Pejovic
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2012-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22253870/?tool=EBI

Similar Items

Claudin7 and moesin in endometrial Adenocarcinoma; a retrospective study of 265 patients
by: Mhawech-Fauceglia Paulette, et al.
Published: (2012-01-01)

The BRCAness Landscape of Cancer
by: Maoni Guo, et al.
Published: (2022-12-01)

Bilateral Ovarian Serous Borderline Tumor with Non-Invasive Endometrial Implants
by: Melissa Bou Malham, et al.
Published: (2023-01-01)

Intersection of DNA Repair Pathways and the Immune Landscape Identifies PD-L2 as a Prognostic Marker in Epithelial Ovarian Cancer
by: Samantha Batman, et al.
Published: (2021-04-01)

Gene expression profiles in stage I uterine serous carcinoma in comparison to grade 3 and grade 1 stage I endometrioid adenocarcinoma.
by: Paulette Mhawech-Fauceglia, et al.
Published: (2011-03-01)

Expression of the luteinizing hormone receptor (LHR) in ovarian cancer
by: Shigang Xiong, et al.
Published: (2019-11-01)

Paratubal serous borderline tumor in an 85 years old woman: A case report
by: Jordy Mehawej, et al.
Published: (2020-05-01)

BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme
by: Mary-Ann Xavier, et al.
Published: (2021-08-01)

Elevated expression of the serine-arginine protein kinase 1 gene in ovarian cancer and its role in Cisplatin cytotoxicity in vitro.
by: Kunle Odunsi, et al.
Published: (2012-01-01)

<i>Let-7i</i> Reduces Aggressive Phenotype and Induces <i>BRCAness</i> in Ovarian Cancer Cells
by: Evgeny Chirshev, et al.
Published: (2021-09-01)

Endometrioid adenocarcinoma associated with endometrial stromal sarcoma: A rare, often unrecognized collision tumor
by: Grace Kim, et al.
Published: (2015-08-01)

Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness
by: Farzaneh Darbeheshti, et al.
Published: (2022-06-01)

Clinicopathological significance of endoplasmic reticulum stress proteins in ovarian carcinoma
by: Soma Samanta, et al.
Published: (2020-02-01)

Development of a novel BRCAness score that predicts response to PARP inhibitors
by: Masanori Oshi, et al.
Published: (2022-11-01)

DNA methylation-based classifier and gene expression signatures detect BRCAness in osteosarcoma
by: Maxim Barenboim, et al.
Published: (2021-11-01)

DNA methylation-based classifier and gene expression signatures detect BRCAness in osteosarcoma.
by: Maxim Barenboim, et al.
Published: (2021-11-01)

Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes
by: Matvey Mihajlovich Tsyganov, et al.
Published: (2022-12-01)

Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer.
by: Sayeema Daudi, et al.
Published: (2014-01-01)

The disruption of the CCDC6 – PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma
by: Francesco Morra, et al.
Published: (2022-08-01)

Pharmacologic Induction of BRCAness in <i>BRCA</i>-Proficient Cancers: Expanding PARP Inhibitor Use
by: Rachel Abbotts, et al.
Published: (2022-05-01)

A ribosomal gene panel predicting a novel synthetic lethality in non-BRCAness tumors
by: Chao Zhang, et al.
Published: (2023-05-01)

Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism.
by: Jianqun Liao, et al.
Published: (2014-01-01)

Microarray analysis reveals distinct gene expression profiles among different tumor histology, stage and disease outcomes in endometrial adenocarcinoma.
by: Paulette Mhawech-Fauceglia, et al.
Published: (2010-11-01)

Risk factors for sporadic ovarian cancer
by: M. M. Vysotsky, et al.
Published: (2014-08-01)

STAT3 imparts BRCAness by impairing homologous recombination repair in Epstein-Barr virus-transformed B lymphocytes.
by: Michael T McIntosh, et al.
Published: (2020-10-01)

Possible pathogenetic types of sporadical ovarian cancer
by: L. A. Ashrafyan
Published: (2014-07-01)

Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer
by: Yue Zhang, et al.
Published: (2023-06-01)

Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness
by: Lars v. B. Andersen, et al.
Published: (2023-06-01)

BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer.
by: Hitomi Mori, et al.
Published: (2016-01-01)

MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue Sarcoma
by: Qi Liu, et al.
Published: (2021-06-01)

Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study
by: Laurie L. Brunette, et al.
Published: (2018-10-01)

BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study
by: Yoshimasa Kosaka, et al.
Published: (2020-02-01)

BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer
by: Esther H. Lips, et al.
Published: (2020-07-01)

THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors
by: Pavithra Shyamsunder, et al.
Published: (2022-01-01)

Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab
by: Tijana Skrepnik, et al.
Published: (2017-03-01)

EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer.
by: Hughes-Davies, L, et al.
Published: (2003)

Molecular Analysis of Mixed Endometrioid and Serous Adenocarcinoma of the Endometrium.
by: Kate Lawrenson, et al.
Published: (2015-01-01)

Distinct Patterns of Structural and Numerical Chromosomal Instability Characterize Sporadic Ovarian Cancer
by: Jane Bayani, et al.
Published: (2008-10-01)

Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases.
by: Alexandra V Stavropoulou, et al.
Published: (2013-01-01)

Pathological Findings in Cetaceans Sporadically Stranded Along the Chilean Coast
by: Mario Alvarado-Rybak, et al.
Published: (2020-08-01)